HK Stock Market Move | INNOVENT BIO(01801) falls more than 3% completing global strategic cooperation with Takeda Pharmaceutical, issuing 6.91 million shares to raise approximately HK$777 million in net proceeds.

INNOVENT BIO (01801) fell more than 3%, dropping 2.73% to HK$91 as of the time of writing, with a trading volume of HK$416 million. On the news front, on December 5th, INNOVENT BIO announced a global strategic partnership with Takeda Pharmaceuticals (through Takeda Pharmaceuticals International AG, a wholly-owned subsidiary of Takeda Pharmaceuticals). All the preconditions for the license, options, and collaboration agreements as well as the share subscription agreement have been fulfilled or waived (as applicable). As a result, the license, options, and collaboration agreements have been completed, and the share subscription agreement was completed on December 4, 2025. Following the completion of the share subscription agreement, the company issued and allocated 6.9138 million shares to the subscribers, representing approximately 0.40% of the company's issued share capital after the subscription. The total proceeds from the issuance and subscription of shares amount to approximately HK$778 million (calculated based on a subscription price of HK$112.56 per share), with net proceeds of approximately HK$777 million.